Evidence map›Paper›PMID 36195095›Full record

ArticleCell reports. Medicine2022

Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes.

Santosh Lamichhane, Partho Sen, Alex M Dickens, Marina Amaral Alves, Taina Härkönen, Jarno Honkanen, Tommi Vatanen, Ramnik J Xavier, Tuulia Hyötyläinen, Mikael Knip and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Trial
  2. Review
  3. Metagenomic Insights into Gut Microbiota Alterations FollowingInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. FXR and BET signaling orchestrate to protect β cells.bioRxiv : the preprint server for biology · 2026
    Article
  6. [Gut microbiota dysbiosis in type 1 diabetes mellitus: Impacts, mechanisms, and interventions].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Santosh LamichhaneTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Partho SenTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden.
Alex M DickensTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; Department of Chemistry, University of Turku, 20520 Turku, Finland.
Marina Amaral AlvesTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; Walter Mors Institute of Research on Natural Products, Federal University of Rio de Janeiro, 21941-599 Rio de Janeiro, Brazil.
Taina HärkönenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jarno HonkanenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Tommi VatanenThe Liggins Institute, University of Auckland, Auckland, New Zealand; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ramnik J XavierThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Tuulia HyötyläinenSchool of Science and Technology, Örebro University, Örebro, Sweden.
Mikael KnipResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
Matej OrešičTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden. Electronic address: matej.oresic@oru.se.

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

The gut microbiota is crucial in the regulation of bile acid (BA) metabolism. However, not much is known about the regulation of BAs during progression to type 1 diabetes (T1D). Here, we analyzed serum and stool BAs in longitudinal samples collected at 3, 6, 12, 18, 24, and 36 months of age from children who developed a single islet autoantibody (AAb) (P1Ab; n = 23) or multiple islet AAbs (P2Ab; n = 13) and controls (CTRs; n = 38) who remained AAb negative. We also analyzed the stool microbiome in a subgroup of these children. Factor analysis showed that age had the strongest impact on both BA and microbiome profiles. We found that at an early age, systemic BAs and microbial secondary BA pathways were altered in the P2Ab group compared with the P1Ab and CTR groups. Our findings thus suggest that dysregulated BA metabolism in early life may contribute to the risk and pathogenesis of T1D.

Indexed as

Diabetes Mellitus, Type 1Islets of LangerhansAutoantibodiesAutoimmunityBile Acids and SaltsChildHumansAutoantibodiesBile Acids and Saltsbile acidgenome-scale metabolic modelinggut microbiomeislet autoimmunitylipid metabolismlipidomicsmetabolomicsmicrobial metabolismtype 1 diabetes

Identifiers

PMID36195095
PMCPMC9589006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.